[Yeouido Investment HQ Part 1] GigaVis, DreamCIS: Stocks Destined for the Hall of Fame?
Predicted impact: Low
TV stock-picking segment with no company-specific facts or filings.
DreamCIS드림씨아이에스
223250 · KOSDAQ · ₩223250 · 드림씨아이에스
₩3,955▲ ₩200 (5.33%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −22.45%
- Market cap
- ₩97B
- Enterprise value
- ₩91B
- P/E
- 295.9×
- P/B
- 1.3×
- Dividend yield
- 0.0%
- ROE
- 0.4%
- Net margin
- 0.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−54.2% from the high
₩2,360Today: ₩3,795 – ₩4,155₩8,640
Returns
- 1W+5.3%
- 1M+20.2%
- 3M+43.3%
- 6M−22.5%
- YTD−38.0%
- 1Y−22.5%
- Volume today
- 454,483
- 0.9× the 20-day average
- Traded today
- ₩1.8B
- Listed shares
- 24,600,444
- EPS (12 months)
- ₩13
- Earnings yield 0.3%
AI research · InitiationDreamCIS: Strong Share Price Rebound Meets Sharply Lower Trailing ProfitThe data shows a company with growing revenue, positive operating profit, net cash of about ₩6.8B (cash less borrowings) and positive free cash flow.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+5.3% on Oct 27, 2026.
- • Foreign investors bought a net ₩274M that day
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumStrong14.3% over the last month; the price is above its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
DreamCIS stock overview
DreamCIS (드림씨아이에스, KRX: 223250) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean contract research organization (CRO) that provides clinical development services to pharmaceutical, biotech, medical device and research clients, including clinical trials, post-marketing surveillance (PMS), clinical quality control, data management and statistical analysis. Its shares closed at ₩3,955 on Oct 27, 2026, up 5.33% on the day, giving it a market value of ₩97B.
Key facts
- Market cap
- ₩97B
- Sector
- Biotech & Pharma
- Latest price change
- +5.33%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean contract research organization (CRO) that provides clinical development services to pharmaceutical, biotech, medical device and research clients, including clinical trials, post-marketing surveillance (PMS), clinical quality control, data management and statistical analysis.
Quick answers about DreamCIS
- What does DreamCIS do?
- The company is a Korean contract research organization (CRO) that provides clinical development services to pharmaceutical, biotech, medical device and research clients, including clinical trials, post-marketing surveillance (PMS), clinical quality control, data management and statistical analysis. It states it has led the domestic CRO market for over 25 years and that a Chinese TOP CRO acquired a stake in the company in 2015. Its operations are centered in South Korea, and it describes itself as positioning for growth as a global CRO.
- What is the market cap of DreamCIS?
- The market capitalisation of DreamCIS was ₩97B at the close on Oct 27, 2026.
- Who are the largest shareholders of DreamCIS?
- According to the latest official filings, the largest reported holders are HONGKONGTIGERMED (71.48%, as of Jan 19, 2026); Yoo Jeong-hee (5.23%, as of May 26, 2026); Yang Tae-sik (0.20%, as of Jun 26, 2026).
- When is the next earnings report from DreamCIS?
- Korean companies rarely announce results dates in advance. Based on when DreamCIS filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
The company is a Korean contract research organization (CRO) that provides clinical development services to pharmaceutical, biotech, medical device and research clients, including clinical trials, post-marketing surveillance (PMS), clinical quality control, data management and statistical analysis. It states it has led the domestic CRO market for over 25 years and that a Chinese TOP CRO acquired a stake in the company in 2015. Its operations are centered in South Korea, and it describes itself as positioning for growth as a global CRO.
Written by AI from the company's latest annual report.
- Korean name
- 드림씨아이에스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 유정희
- Founded
- Apr 2000
- Listed
- May 2020
- Listed shares
- 24,600,444
- Fiscal year ends
- Month 12
- Website
- www.dreamcis.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- Half-year report (Jun 2026)Aug 13, 2026
- Amended: Major sales or supply contractAug 11, 2026
- Insider shareholding reportJun 26, 2026
- Insider shareholding reportJun 26, 2026
- Investor relations (IR) eventJun 17, 2026
Titles in Korean until English translations are added.
Also known as: DreamCIS / 드림씨아이에스 / 223250 / KRX:223250
Source: KRX statistical information